Skip to content

A Study on Sumac Mouth Rinse for Treating Recurrent Aphthous Stomatitis

Sumac Mouth Rinse in the Management of Recurrent Aphthous Stomatitis (A Randomized Controlled Clinical Study With Biochemical Assessment)

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07229469
Acronym
SUMAC-RAS
Enrollment
38
Registered
2025-11-17
Start date
2023-12-20
Completion date
2025-08-18
Last updated
2026-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent Aphthous Stomatitis

Keywords

Sumac, Rhus coriaria, mouth rinse, recurrent aphthous stomatitis, oral ulcers, TNF-alpha, anti-inflammatory, herbal therapy, clinical trial

Brief summary

This randomized controlled clinical study aims to evaluate the effectiveness of a Sumac mouth rinse in the management of recurrent aphthous stomatitis (RAS). In addition to assessing clinical improvement in ulcer healing and pain reduction, biochemical analysis will be performed by measuring serum TNF-α levels to evaluate the anti-inflammatory effect of Sumac.

Detailed description

Recurrent aphthous stomatitis (RAS) is one of the most common oral mucosal disorders, characterized by recurrent, painful ulcers that interfere with eating and speaking. The etiology of RAS is multifactorial and involves immune dysregulation and increased levels of inflammatory cytokines, particularly tumor necrosis factor-alpha (TNF-α). Sumac (Rhus coriaria) is a natural herbal extract known for its anti-inflammatory, antioxidant, and antimicrobial properties. This randomized controlled clinical study aims to evaluate the clinical effectiveness of a Sumac mouth rinse in promoting ulcer healing and reducing pain among patients with recurrent aphthous stomatitis. In addition to clinical assessment, biochemical evaluation of serum TNF-α levels will be performed before and after treatment to investigate the possible anti-inflammatory mechanism of Sumac. The study findings are expected to provide new insights into the potential therapeutic role of Sumac in managing RAS.

Interventions

OTHERSumac mouth rinse

Herbal mouth rinse containing Sumac extract

DRUGTantum Verde mouth rinse

Standard mouth rinse according to manufacturer instructions

Sponsors

Ain Shams University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Masking description

Both participants the outcomes assessor and the researcher were blinded to the treatment allocation. The Sumac mouth rinse and placebo were identical in appearance, color, and packaging and were stored in amber bottles to maintain blinding throughout the study.

Intervention model description

A parallel, randomized controlled clinical trial with two groups: one group received Sumac mouth rinse and the control group received Tantum Verde mouth rinse . Participants were randomly assigned to each group. Both participants , the outcomes assessor and the researcher were blinded to group allocation.

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
Yes

Inclusion criteria

* Patients aged 18 years or older * Systemically healthy * Patients with recurrent aphthous stomatitis minor type * Duration of ulcer does not exceed 2 days * Oral pain score of 4 or higher on the Visual Analog Scale (VAS)

Exclusion criteria

* Patients with poor oral hygiene * Smokers and alcohol users * Pregnant or lactating females * Patients with a history of any topical or systemic medication or steroid therapy within 1 month prior to the study * Vulnerable populations such as prisoners or individuals with mental or physical disabilities

Design outcomes

Primary

MeasureTime frameDescription
Pain (VAS)At the baseline / Day 2 / Day 6Visual Analog Scale (VAS) to assess the intensity of oral ulcer pain reported by the patient, where 0 indicates no pain and 10 indicates the worst imaginable pain.
Ulcer sizeAt the baseline / Day 2 / Day 6Measurement of the oral ulcer diameter in millimeters using a ruler or photographic analysis to evaluate ulcer size reduction over time.

Secondary

MeasureTime frameDescription
Healing indexAt the baseline / Day 2/ Day 6Healing index included four categories: 1. Complete reepithelialization 2. Incomplete reepithelialization 3. Ulcer 4. Tissue defect or necrosis
TNF- alphaAt the baseline/ Day 6Quantification of the inflammatory cytokine TNF-α in blood or saliva using ELISA to evaluate the inflammatory response associated with oral ulcers.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 9, 2026